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In this review we ﬁrst present the anatomical pathways used by the suprachiasmatic nuclei to
enforce its rhythmicity onto the body, especially its energy homeostatic system. The experimental
data show that by activating the orexin system at the start of the active phase, the biological clock
not only ensures that we wake up on time, but also that our glucose metabolism and cardiovascular
system are prepared for increased activity. The drawback of such a highly integrated system, how-
ever, becomes visible when our daily lives are not fully synchronized with the environment. Thus, in
addition to increased physical activity and decreased intake of high-energy food, also a well-lighted
and fully resonating biological clock may help to withstand the increasing ‘‘diabetogenic’’ pressure
of today’s 24/7 society.
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k).autonomous endogenous clock developed in the brain to coordinate
and anticipate our behavior and metabolism according to the envi-
ronmental periodicity induced by the earth’s rotation. A proper
entrainment of this endogenous clock mechanism to the outside
world is ensured by a number of input signals, of which light, food
intake and activity are the most important ones. The biological
clock, located in the suprachiasmatic nucleus (SCN) of the anterior
hypothalamus, consists of several clusters of small and densely
packed neurons in which various peptidergic transmitters are
expressed [1]. The entraining signals from light, feeding and
locomotor activity are relayed to the SCN via direct projections from
the retina, the arcuate nucleus and the raphe nucleus, respectively.
The direct projection from the intergeniculate leaﬂet to the SCN
seems to be an important secondary route for all three entraining
signals. The afferent projections from these different brain struc-
tures use, among other things, glutamate, pituitary adenylcyclase
activating peptide (PACAP), neuropeptide Y (NPY), neuropeptide
FF (NPFF) and serotonin as a neurotransmitter [2]. The endogenous
clock mechanism consists of interlocking transcriptional-
translational feedback loops, and contains genes necessary forlsevier B.V. All rights reserved.
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controlled output genes that impose their rhythmicity on the rest of
the hypothalamus and beyond [3]. A few of the peptidergic SCN
transmitters, i.e. vasopressin, vasoactive intestinal peptide (VIP),
cardiotrophin-like cytokine and prokineticin-2, have already been
identiﬁed as so-called clock-controlled genes [4–7]. Subsequently,
the rhythmic output of this endogenous clock is conveyed to the
endocrine and metabolic systems via efferent projections from
the SCN to both neuroendocrine and pre-autonomic neurons in
the hypothalamus [8]. Here we discuss the hypothesis that in to-
day’s society the output of the biological clock is unbalanced due
to insufﬁcient or even contradictory input signals to the SCN, ham-
pering its proper entrainment to the outside world and thus also
hampering proper entrainment of its output.
2. SCN outputs
In 1972, it became clear that the SCN in the anterior hypothal-
amus was the seat of the central biological clock [9]. Only a few
years after this discovery it was demonstrated that the SCN con-
tains a prominent population of vasopressin-containing neurons
[10,11]. Due to its pronounced day/night rhythm in the cat cere-
brospinal ﬂuid (CSF) [12,13], vasopressin was soon characterized
as an output of the SCN. This important ﬁnding was followed by re-
ports on vasopressin-containing neurons in the SCN of a large vari-
ety of species [14–20], as well as CSF vasopressin rhythms in a
number of species, including monkey, rat, guinea pig, goat, sheep
and rabbit [21–25]. Neither lesions of the paraventricular nucleus
of the hypothalamus (PVN), nor hypophysectomy or pinealectomy
were able to eliminate this rhythm. The rhythms were even sus-
tained after complete isolation – by circular knife cuts – of the
SCN in vivo. Only complete SCN lesions abolished the rhythm
and in most cases reduced CSF vasopressin levels to below detec-
tion level [26,27]. In addition, it was demonstrated that also
in vitro the rhythmic release of vasopressin from the SCN is main-
tained for several days [28,29]. Moreover, studies on the circadian
ﬂuctuation of messenger RNA (mRNA) showed an elevation, or
poly-A tail elongation, of vasopressin mRNA in the SCN during
the light period [30,31], whereas PVN and supraoptic nuclei
(SON) vasopressin mRNA showed no such diurnal ﬂuctuations.
Similar observations, i.e., pronounced daily ﬂuctuations in the
SCN, but not in the PVN and SON, were made for the extracellular
levels of vasopressin in the SCN, PVN and SON [32].
Since then, many SCN transmitters other than vasopressin have
come to be recognized [33], most of which also show a clear day/
night rhythm in the amount of protein or mRNA expression in the
nucleus itself. However, until now VP is still the only SCN output
that has been demonstrated to be secreted in a circadian rhythm
in vivo. Transplantation and parabiosis experiments have unequiv-
ocally demonstrated that non-neuronal mechanisms do not sufﬁce
when it comes to reinstating circadian rhythms in all peripheral or-
gans [34–36]. Moreover, an elegant experiment by de la Iglesia et al.
[37] provided clear functional evidence for the necessity of point-
to-point neural connections in order to sustain neuroendocrine
rhythms. So where does the rhythmic information that is generated
within the SCN go? Information on the distribution of SCN projec-
tions was initially obtained from neuro-anatomical studies using
tracing, immunocytochemistry, SCN lesions, or a combination of
these methods [38–40]. All these studies showed that the outﬂow
of SCN information was in fact surprisingly limited and pertained
to the medial hypothalamus, in particular to target areas that
contain mainly interneurons, such as the medial preoptic area
(MPOA), dorsomedial nucleus of the hypothalamus (DMH) and sub-
paraventricular nucleus of the hypothalamus (subPVN) (Fig. 1).
Although much more scarce, direct connections to neuroendocrineneurons (i.e., corticotrophin-releasing hormone (CRH)-, TRH-, TH-
and GnRH-containing) in the PVN, arcuate nucleus and MPOA,
and pre-autonomic neurons in the PVN were described as well
[41–48]. In a series of micro-infusion studies we were able to show
how the SCN uses these neural connections to control peripheral
rhythms in hormone release and energy metabolism [8,49,50].
The daily ﬂuctuations of vasopressin in the CSF are a result of the
day/night rhythm in the ﬁring rate of vasopressin-containing SCN
neurons [51] (Fig. 2), and the close proximity of the vasopressin
containing SCN projections to the ventricular space, i.e., in the
MPOA, the periventricular nucleus of the hypothalamus (pePVN)
and subPVN, the DMH and the PVN.
3. SCN control of hormonal rhythms
The data presented above make a strong case for a prominent
role of vasopressin as an output signal of the hypothalamic biolog-
ical clock. In view of all this evidence in favor of an important role
for vasopressin in the output from the SCN we began, in 1992,
with microinfusions of vasopressin and its antagonist. These ﬁrst
experiments demonstrated that vasopressin released from SCN ter-
minals has a strong inhibitory control over basal plasma corticoste-
rone concentrations [52]. Further studies on the relation between
the circadian release of vasopressin and the control of the daily
rhythm in the activity of the hypothalamo-pituitary-adrenal
(HPA)-axis revealed that vasopressin release in the rat DMH is
important to ensure low circulating levels of corticosterone during
the ﬁrst half of the light period [53]. In addition, the subsequent
halt of vasopressin release from these SCN terminals in the DMH
is a prerequisite for the daily surge in plasma corticosterone before
the onset of the main activity period of the nocturnal rat, i.e., the
dark period [54]. This series of experiments also clearly showed
that vasopressin is not the only SCN signal involved in the control
of the daily rhythm in HPA-activity, but that the general principle
of SCN control over daily (hormone) rhythms seems to be a push-
and-pull or ying-yang mechanism, based upon an alternation of
stimulatory and inhibitory inputs to the appropriate target
neurons.
3.1. The importance of intermediate neurons
In the case of the HPA-axis the most likely target neurons ap-
peared to be the CRH-containing neurons in the PVN. However,
some evidence was inconsistent with this as a primary role for
CRH neurons. Firstly, a direct effect of vasopressin on the CRH neu-
ron would imply a clear daily rhythm in plasma adrenocorticotro-
phic hormone (ACTH) concentrations, but this was not observed.
Secondly, the observed inhibitory effect of vasopressin was not in
line with the usual excitatory effect of vasopressin on its target
neurons. Thirdly, contrary to the expected abundant contacts be-
tween SCN-derived vasopressin ﬁbers and CRH neurons, only a
limited amount of such connections was found [42,55]. A detailed
anatomical scheme incorporating all of the above and explaining
our current view on the SCN control of the daily rhythm in HPA-
activity is shown in Fig. 3. The proposed intermediate role of the
gamma amino butyric acid (GABA)-ergic neurons in the subPVN
and DMH in rats is supported by electrophysiological in vitro
experiments using hypothalamic slices [56]. As the image on the
right of Fig. 3 shows, the proposed important role for intermediate
areas such as the subPVN and DMH also provides a good explana-
tion for the mechanism behind the 12-h reversal of certain
rhythms in nocturnal and diurnal species (for instance that of
HPA-axis activity) [57], when apparently the phase of SCN activity
(including vasopressin release) is similar for nocturnal and diurnal
species [58,59].
Fig. 1. Darkﬁeld illustration of SCN projections into the hypothalamic paraventricular (PVN), dorsomedial (DMH) and ventromedial (VMH) hypothalamus. After the
iontophoretic injection of Phaseolus vulgaris leucoagglutinin (PHA-L) into the SCN a large concentration of labeled ﬁbers can be observed in the area just ventral to the PVN
(upper panel), also known as the sub-paraventricular zone or the subPVN. Less dense but also clearly innervated in the upper panel are the periventricular part and the
dorsomedial part of the PVN, but note the almost complete lack of labeled ﬁbers in the parvicellular and magnocellular parts of the PVN. Caudal to the PVN (lower panel) a
dense terminal ﬁeld of SCN ﬁbers can be observed in the DMH. In the lower panel also a clear concentration of PHA-L labeled ﬁbers is present in the area between the arcuate
nucleus (ARC) and the VMH, as well as the area lateral to the VMH. The third ventricle (III) is on the right side (upper panel) or left side (lower panel).
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An important spin-off of the above-mentioned vasopressin
experiments was the insight it provided into the outﬂow of SCN
information to the autonomic nervous system (ANS) as an impor-
tant mediator for the SCN control of peripheral organs and tissues.
The mismatch between plasma ACTH and plasma corticosterone
concentrations and responses made us realize that the ANS might
be important for setting the sensitivity of the adrenal cortex to
ACTH. Transneuronal virus tracing from the adrenal indeed re-
vealed second-order labeling in PVN neurons, and third-order
labeling in SCN neurons [60]. The functional importance of this
multi-synaptic connection between the SCN and the adrenal cortex
for the daily rhythm in adrenal corticosterone release was proven
later on by an elegant combination of adrenal microdialysis and
denervation experiments [61]. The SCN thus apparently uses atwo-stage mechanism to control daily hormone rhythms: on the
one hand it acts on the neuroendocrine motorneurons to inﬂuence
the release of hypothalamic releasing factors, on the other hand it
also acts – through the ANS – on the target tissues to inﬂuence the
sensitivity to the incoming hormonal message.
4. SCN control of the sympathetic nervous system
4.1. The daily melatonin rhythm
The prime example of circadian control through the ANS is the
daily rhythm in melatonin release from the pineal gland. Ulti-
mately the synthesis and release of melatonin are controlled by
the sympathetic input to the pineal gland [62]. A similar pathway,
with potential relevance for sleep disturbances, is most likely to be
present in humans [63,64]. Based on a series of experiments very
Fig. 2. Mean ﬁring frequency of vasopressin-positive, vasopressin-negative, and
non-characterized neurons analyzed in the in vitro dorsal SCN of the rat. The ﬁring
frequency was determined in hypothalamic slices at either CT5–8 or CT14–17. All
groups showed a signiﬁcant effect of diurnal timing. However, the difference was
only two-fold in the vasopressin-negative neurons, whereas it amounted to ﬁve- or
six-fold in the vasopressin-positive neurons. Especially the nocturnal ﬁring
frequency rate of vasopressin-positive neurons was remarkably lower as compared
to the other groups. With permission from Buijs et al. (2006). ⁄⁄⁄P < 0.001;
⁄,#P < 0.05
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function of vasopressin in the circadian control of the HPA-axis,
we found that the daily rhythm in plasma melatonin concentration
is also generated by a combination of stimulatory and inhibitory
SCN outputs. We proposed that the activity of the pre-autonomic
PVN neurons that are in charge of the sympathetic input to the
pineal gland is controlled by a combination of glutamatergic andFig. 3. Detailed anatomical scheme of demonstrated and putative⁄ connections of the su
opposite effects of vasopressin on the HPA axis in these two species. Vasopressin is rel
ansorgei. In rats vasopressin release during the light period will inhibit the corticotropin
hypothalamus (PVN) by contacting c-aminobutyric acid (GABA)ergic interneurons in the
the Arvicanthis ansorgei, vasopressin release during the light period will stimulate CRH
interneurons in the subPVN and DMH. ⁄Only the projections from the subPVN and DMH
experiments. With permission from Kalsbeek et al. (2008).GABA-ergic inputs from the SCN [65–68]. The circadian and
light-induced daytime activity of the GABA-ergic SCN projections
to the PVN ensures low melatonin levels during the light period.
The nocturnal arrest of the inhibitory GABA-ergic inputs, combined
with the continuously active glutamatergic inputs, enables the pre-
autonomic PVN to become active again and start a new period of
melatonin synthesis and release.
4.2. Shifting the melatonin rhythm
To further deﬁne the subpopulations of SCN neurons responsi-
ble for these inhibitory and stimulatory signals we used a combi-
nation of two different experimental paradigms, i.e., an 8-h
advance of the light/dark (L/D)-cycle and a time-restricted feeding
(RF) regime. After an 8-h phase advance of the L/D-cycle it takes
at least 5 days for the nocturnal peak of melatonin release to re-
appear at the appropriate time of day [69]. This entrainment is
postponed even further when the animals are on a restricted
daytime feeding schedule before the shift [70]. The abrupt
phase-shift induced by the 8-h advance of the L/D-cycle pro-
foundly affects the spatial and temporal distribution of Per clock
gene expression in the SCN. We therefore investigated whether
the activation of a particular subpopulation of SCN neurons could
be correlated with the reappearance of either the onset or the off-
set of the plasma melatonin peak [71]. From the results of these
experiments we concluded that there is a small subset of Per
expressing neurons located in the central part of the SCN that is
responsible for the nocturnal stimulation of melatonin release
during the dark period. We propose that these neurons provide
the necessary glutamatergic input to the PVN. In addition, an ab-
sence of Per expression in the dorsal part of the SCN also seems aprachiasmatic nucleus (SCN) in the rat and Arvicanthis ansorgei brain to explain the
eased during the light period, both in the nocturnal rat and the diurnal Arvicanthis
-releasing hormone (CRH)-containing neurons in the paraventricular nucleus of the
subPVN and dorsomedial nucleus of the hypothalamus (DMH). On the other hand, in
-containing neurons because it acts on the glutamatergic, instead of GABAergic,
to the PVN in the Arvicanthis ansorgei have not been formerly conﬁrmed by tracing
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i.e., compare the CT14–CT22 Per1 expression in ad libitum (AL)
and RFs animals (Fig. 4). We hypothesize that it is the ‘‘activity’’
of these dorsal SCN neurons (and their sustained release of GABA)
in the shifted animals that inhibits the pre-autonomic neurons in
the PVN and prevents the reappearance of a new melatonin peak
in the shifted dark period.
4.3. Desynchronizing the melatonin rhythm
Schwartz and de la Iglesia have developed a forced desynchrony
(FD) protocol in rats that results in a stable dissociation of rhyth-
mic clock gene expression in the ventrolateral and dorsomedial
SCN [72]. In these animals the rhythms of locomotor activity, sleep,
body temperature and melatonin release are internally desynchro-Fig. 4. Spatial and temporal distribution of Per1 gene expression in the SCN, throughout
libitum fed animals that had been phase-shifted (8-h) 5 days earlier (ALs), and for anima
Per1 gene expression was revealed by the non-radioactive immuno-in situ hybridization t
Gray and black bars on the left side of the ﬁgures indicate light and dark portions of the L/
8-h phase-advance of the L/D-cycle was realized by shutting down the light at ZT4. The R
ﬁrst day of the shift, the animals were provided with food ad libitum. Starting at ZT10 o
groups were maintained in constant darkness under red-dim-light until the end of the ex
different time points starting at CTs14 on D5 (CTs14 indicating CT14 after the shift an
Stephanie Perreau-Lenz (2004).nized [72–74]. These experiments provided a clear example of how
the normal phase relation between different compartments of the
SCN may be disorganized, thereby profoundly affecting behavioral
and hormonal rhythmicity. Whether or not similar internal desyn-
chrony occurs in humans when there is misalignment of the
endogenous circadian rhythms of melatonin, temperature, and
cortisol with the behavioral sleep/wake and fasting/feeding cycle,
remains to be investigated. This would be clinically relevant in
relation to the adverse health consequences that night shift
workers experience [75].
5. SCN control of the parasympathetic nervous system
On the basis of a series of retrograde viral tracing studies from
adipose tissue (both brown and white), pancreas, stomach, and thethe L/D-cycle. Per1 gene expression is shown for ad libitum fed animals (AL), for ad
ls on a restricted-feeding protocol that had been phase-shifted 5 days earlier (RFs).
echnique (with the help of Dr. Hugues Dardente, in the laboratory of Dr. Paul Pévet).
D-cycle. Animals on restricted feeding (RF) had daily access to food from ZT4–6. The
F animals had been on the RF protocol for 4 weeks before the phase-shift. From the
n day 5 after the shift (D5) and ZT2 for the non-shifted groups, the animals of the 3
periment. The animals of the AL, ALs, and RFs groups were perfused every 4-h at six
d corresponding to ZT6 in non-shifted time). For further details see the thesis of
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adrenal and pineal gland may apply for other peripheral tissues as
well [76–79], certainly for tissues involved in energy metabolism.
Thus we hypothesized that part of the action of the SCN to prepare
our bodies for the alternating periods of sleep and wakefulness
would be through the use of its connections with the hypothalamic
pre-autonomic neurons to control the daily setting of the sympa-
thetic – parasympathetic balance of autonomic inputs to these
peripheral organs. Indeed, in a ﬁrst series of viral tracing
experiments we were able to show a clear separation of the pre-
autonomic neurons that control the sympathetic and parasympa-
thetic branch of the ANS, up to the level of the second order
neurons in the hypothalamus [76,80,81]. Subsequently, we investi-
gated whether one single group of neurons within the biological
clock would be dedicated to the control of these sympathetic and
parasympathetic pre-autonomic neurons, in other words, whether
also within the SCN there is a clear separation of neurons control-
ling the sympathetic and parasympathetic branches of the ANS.
Using a combination of double viral tracing and selective organFig. 5. The suprachiasmatic nucleus (SCN) balances sympathetic and parasympathetic o
panel the experimental setup used to examine the possible separation of sympathetic a
schematic drawing of a sagittal section of the rat brain. D-galactoside PRV (bGAL-PRV) wa
via the vagus nerve (red lines); simultaneously the pre-sympathetic neurons were labe
lines). After the labeling of the ﬁrst-order neurons in the brainstem and spinal cord, this
the PVN (second order), followed by a similar separation of the third-order neurons in th
the SCN (left) and PVN (right) show a perfect separation of pre-parasympathetic bGAL-PRV
(i.e., double-labeled) neurons. Scale bar = 25 lm. With permission adapted from Buijs edenervation we were able to demonstrate that the segregation of
pre-sympathetic and pre-parasympathetic neurons already starts
at the level of the SCN (Fig. 5) [82]. This high level of differentiation
puts the SCN in a unique position to balance the activity of both
ANS branches according to the time of day. However, although
these neuro-anatomical data provide a nice blueprint for the pos-
sible SCN control of energy metabolism and the autonomic bal-
ance, the big question remains whether, and if so, to what extent
this neuro-anatomical blueprint has any functional signiﬁcance.
5.1. A daily rhythm in plasma glucose concentrations
To investigate whether the SCN control of the parasympathetic
branch of the ANS would be comparable to the one just described
for the sympathetic branch, we then focused our attention on the
daily rhythm in plasma glucose concentrations. Maintaining a con-
stant blood glucose level is essential for normal physiology in the
body, particularly for the central nervous system (CNS), as the
CNS can neither synthesize nor store the amount of glucoseutput to peripheral organs through separate pre-autonomic neurons. In the upper
nd parasympathetic pre-autonomic neurons in the hypothalamus is indicated in a
s injected into the sympathetic denervated liver, forcing the virus to infect the brain
led by an injection of green ﬂuorescent protein (GFP)-PRV into the adrenal (green
approach resulted in separate pre-parasympathetic and pre-sympathetic neurons in
e SCN. In the lower panels transverse sections of the hypothalamus in the region of
(red) and pre-sympathetic GFP-PRV (green) labeled neurons, as there are no yellow
t al. (2003).
Fig. 6. Orexin release is necessary for the endogenous rise in glucose appearance at
dusk in nocturnal animals. The endogenous rise in glucose appearance (Ra) during
ICV vehicle administration is shown in the left panel. ICV administration of the
orexin antagonist, during the latter part of the light period, prevents the
endogenous rise of Ra before the onset of darkness (ZT11–ZT12), and during the
onset of the dark period (ZT12–ZT15) (right panel). The orexin antagonist SB-
408124 was administered ICV from ZT4–ZT12. IV administration of the orexin
antagonist had no effect on glucose appearance. Food intake was not changed by
ICV orexin. s and 4, P < 0.05 compared with ZT4–6 and ZT6–11, respectively.
⁄P < 0.05 compared with comparable time points in the vehicle group.
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role in maintaining optimum glucose levels by balancing glucose
entry into, and its removal from, the circulation. From a hypotha-
lamic and chronobiological point of view glucose production by
the liver is especially interesting because of the clear involvement
of both the sympathetic and parasympathetic input to the liver in
glucose metabolism [83–85] and the strong circadian control of
(glucose) metabolism in the liver [86–88]. Using local intra-
hypothalamic administration of GABA and glutamate receptor
(ant)agonists we explored the contribution of changes in ANS
activity to the daily control of plasma glucose and plasma insulin
concentrations. The daily rhythm in plasma glucose concentrations
turned out to be controlled according to a mechanism very much
similar to the mechanism just described for the SCN control of
the daily rhythm in melatonin release, i.e., a combination of rhyth-
mic GABA-ergic inputs and continuous glutamatergic stimulation
onto liver-dedicated sympathetic pre-autonomic neurons in the
PVN [81,89]. The major difference between the liver-dedicated
and pineal-dedicated pre-autonomic neurons seems to be the tim-
ing of the GABA-ergic inputs. In the case of the pineal-dedicated
pre-autonomic neurons this inhibitory input is present during
the major part of the light period with an acrophase around ZT6,
whereas for the liver-dedicated pre-autonomic neurons the acro-
phase of the GABA-ergic inhibition is somewhere around ZT2. Sur-
prisingly, no clear evidence was found for an involvement of the
parasympathetic branch of the ANS, as our previous denervation
studies clearly showed the daily plasma glucose rhythm to be dis-
rupted, also in parasympathetic liver-denervated animals [90].
5.2. The daily glucose rhythm and the perifornical orexin neurons
Plasma glucose concentrations are the result of a glucose inﬂux
from the gut and liver, and glucose efﬂux by its uptake in brain,
muscle, and adipose tissue. To investigate in more detail by which
glucoregulatory mechanism the just described SCN output mecha-
nism contributes to the increased plasma glucose concentrations at
awakening we ﬁrst performed a series of intravenous glucose tol-
erance and insulin sensitivity tests in rats. To our surprise these
studies revealed that glucose tolerance and insulin sensitivity peak
at the onset of the dark period [91]. Therefore, the rise in plasma
glucose concentrations at the end of the sleep period could not
be explained by a diminished glucose uptake at this time of the
L/D-cycle. These studies also indicated that glucose production
should increase at the end of the sleep period, ﬁrstly to compensate
for the increased glucose uptake and secondly to explain the in-
creased plasma glucose concentrations. We went on to combine
hypothalamic administration studies with systemic infusion of a
stable glucose isotope. The use of the stable glucose isotope en-
abled us to distinguish between changes in glucose production
and glucose uptake. These experiments showed that a pronounced
increase in hepatic glucose production was caused by the adminis-
tration of bicuculline (a GABA-A receptor antagonist) in the peri-
fornical area lateral to the DMH, and that orexin- (but not MCH-)
containing neurons in this area were strongly activated [92]. Sub-
sequent studies revealed that the hyperglycemic effect of bicucul-
line could indeed be prevented by the concomitant ICV
administration of an orexin antagonist and that orexin ﬁbers im-
pinge upon sympathetic preganglionic neurons in the intermedio-
lateral column of the spinal cord (IML) that project to the liver
[92,93]. Earlier we had demonstrated that the hyperglycemic effect
of a focal blockade of GABA-ergic transmission was very much
dependent on the time of day [89], indicating SCN control. Indeed
using an approach very much similar to ours, Alam et al. [94] had
already demonstrated that perifornical orexin neurons are subject
to an increased endogenous GABA-ergic inhibition during sleep. In
view of the pronounced day/night-rhythm in orexin release [95,96]we hypothesized that orexin is the main connection between the
biological clock and the daily rhythm in plasma glucose concentra-
tions. To test this hypothesis we measured the rate of glucose
appearance (Ra) in AL fed animals during the second half of the
light period and the ﬁrst hours of the dark period, i.e., during the
ascending phase of the daily rhythm in plasma glucose. We com-
bined these measurements with the ICV infusion of an orexin
antagonist or vehicle (Fig. 6). The results of this experiment point
to an important role for the orexin system in the control by the bio-
logical clock over daily glucose homeostasis, as the ICV orexin-
antagonist completely prevented the daily dusk time increase in
glucose appearance. The perifornical orexin neurons thus seem to
transduce the rhythmic GABA and glutamatergic signals emanat-
ing from the SCN into a daily activation of the sympathetic input
to the liver, which results in an increased hepatic glucose produc-
tion at the end of the sleep period in anticipation of a new period of
wakefulness. Remarkably, a recent study by Shiuchi et al. [97]
demonstrated that via the ventromedial nucleus of the hypothala-
mus (VMH) and the sympathetic nervous system orexin is able to
stimulate glucose uptake in muscle. Thus, orexin might be an
important link in the SCN-controlled concomitant increase of glu-
cose production and glucose uptake at the onset of the activity per-
iod [91]. Together, these results indicate that by a dis-inhibition of
the orexin system at the end of the light period the SCN not only
promotes arousal, but also causes an increase of endogenous glu-
cose production to ensure adequate concentrations of plasma glu-
cose when the animal awakes. Other studies made it look very
likely that the rhythmic activity of the orexin system is also in-
volved in the increased activity of the cardiovascular system at
awakening [98,99]. However, a major drawback of such a heavily
integrated system may be that, due to their effect on the orexin
system, sleep disturbances will result in hypertension [100] and
disturbed glucose metabolism [101,102].
5.3. The circadian control of meal-induced insulin responses
As has become evident from the daily variation in meal-induced
insulin responses [103], intestinal glucose uptake [104], respira-
tory functioning [105] and markers of cardiac vagal activity
[106–108a,b] the parasympathetic branch of the ANS too, is under
control of the circadian timing system. Our intra-hypothalamic
infusion studies revealed that the daily changes in the activity
of the parasympathetic pre-autonomic neurons also involve a
Fig. 7. Schematic presentation of the daily activity pattern of hypothalamic populations of GABAergic and glutamatergic neurons implicated in the autonomic control of the
daily rhythms in hepatic glucose production (A) and feeding-induced insulin release (B). The sympathetic and parasympathetic pre-autonomic neurons are inhibited by a
rhythmic GABAergic input (green dots and lines) from the SCN that is mainly active during the light period. Sympathetic pre-autonomic neurons are stimulated by
glutamatergic inputs (purple dots and lines) from the SCN (A), whereas parasympathetic pre-autonomic neurons are stimulated by glutamatergic inputs from the VMH (B).
The glutamatergic stimulation only translates in activity of the pre-autonomic neurons when the inhibitory input from the SCN is absent. The control of the sympathetic pre-
autonomic neurons that are involved in the control of the daily melatonin rhythm looks very much similar to that of hepatic glucose production, the only difference being a
slight phase delay of the activity of GABAergic SCN neurons that innervate the ‘‘pineal-dedicated’’ pre-autonomic neurons. With permission from Kalsbeek et al. (2008).
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inhibition of pre-autonomic neurons, both sympathetic and para-
sympathetic, by a daily rhythm in GABA release from SCN efferents
to the PVN turned out to be a general principle. However, a major
difference between the circadian control of parasympathetic and
sympathetic pre-autonomic neurons appears to be the origin of
the excitatory glutamatergic inputs. SCN-lesion studies proved that
the excitatory input to the sympathetic pineal-dedicated pre-
autonomic neurons was derived from the SCN neurons [67],
but also that the glutamatergic inputs to the parasympathetic
pancreas-dedicated pre-autonomic neurons cannot be derived
from SCN neurons [109]. At present, it is not yet clear from which
extra-SCN source the glutamatergic inputs to the parasympathetic
pancreas-dedicated pre-autonomic neurons originate, but likely
candidates are the VMH and arcuate nucleus (Fig. 7).
6. SCN and adipose tissue
Obesity is characterized by excessive accumulation of triglycer-
ides in adipose tissue determined by a net balance of fatty acid up-
take and release in favor of fat storage over fat mobilization. The
rich innervation of adipose tissue by sympathetic ﬁbers is well-
known, and activation of these ﬁbers is associated with enhanced
lipolysis [110]. Until a few years ago, it was thought that parasym-
pathetic innervation of adipose tissue did not occur and that lipo-
genesis was merely controlled by hormones, the mass action of
free fatty acids (FFA’s) and sympathetic withdrawal. In view of
the importance of this balance between lipogenesis and lipolysis,
and the capacity of the SCN to control the sympathetic/parasympa-
thetic balance in other organs, we re-investigated the existence of
parasympathetic input to adipose tissue. This would allow us to
test the possibility of SCN control of this lipogenesis/lipolysis
balance through the ANS. Indeed, as previously reported by others
[111], at ﬁrst we found only very sparse parasympathetic input
to white adipose tissue. However, combining the viral tracing
technique with a prior selective sympathetic denervation of the
targeted fat pad resulted in pronounced labeling of the parasympa-
thetic motorneurons in the brainstem [112]. It is not clear what
causes this increased visibility of the parasympathetic input, but
one possibility is that the parasympathetic ﬁbers are only exposedto the virus when the more active sympathetic ﬁbers have been re-
moved, as previous studies have shown that viral tracing can be
modulated by neuronal activity [113]. These observations provided
the neuro-anatomical substrate for earlier pharmacological obser-
vations in human microdialysis studies that showed cholinergic ef-
fects on lipolysis [114] and the more recent identiﬁcation of
functional acetylcholine receptors in rat adipocytes [115,116]. In
addition, our own functional studies provided clear evidence for
the anabolic function of this parasympathetic innervation of adi-
pose tissue. Euglycemic hyperinsulinemic clamp studies revealed
a >30% reduction in the insulin-mediated uptake of glucose and
FFA’s in adipose tissue as a result of selective removal of its para-
sympathetic input. Moreover, without parasympathetic input the
activity of the catabolic enzyme hormone sensitive lipase (HSL) in-
creased by 51% in the denervated adipose tissue [112]. Follow-up
studies using two different PRV tracers and selective denervation
of the adipose tissue showed the presence of both ‘sympathetic’
and ‘parasympathetic’ adipose neurons in the hypothalamus,
including the SCN [117]. These results thus provide clear evidence
that the SCN may use the ANS to enforce its day/night rhythms
upon the endocrine and metabolic functioning of adipose tissue.
Indeed, both fat deposition by the key enzyme lipoprotein lipase
(LPL) and fat mobilization by HSL show a clear daily rhythm in
the white adipose tissue of humans and laboratory animals
[118–122]. In addition, the circulating plasma levels of a number
of adipocytokines, including leptin, as well as their adipose mRNA
levels show clear day/night rhythms [123–127], while a SCN-lesion
abolishes the diurnal rhythm of plasma leptin [128].
7. Social jetlag
There is accumulating evidence for an intimate relation be-
tween circadian and metabolic cell systems, also at the molecular
level [129,130]. From the data presented above it is clear that the
circadian system has a major inﬂuence on energy metabolism.
The restricted-feeding paradigm shows that the reverse is also
true, i.e., energy metabolism also has a profound effect on the cir-
cadian system. Although the central pacemaker in the SCN seems
to be relatively protected against the disorganizing effects of RF
during the light period, peripheral clock systems in the liver and
Fig. 8. Consequences of circadian misalignment on metabolic and endocrine
function. Data from 10 healthy volunteers are plotted according to time-
since-wake, during normal circadian alignment (open green symbols; scheduled
awakening at habitual wake time) and during circadian misalignment (ﬁlled red
symbols; scheduled awakening 12 h out of phase from habitual wake time). P-
values, statistical signiﬁcance for effect of misalignment; gray area, scheduled sleep
episode; short vertical gray bars, meal times; B, breakfast; L, lunch; D, dinner; S,
snack. Reproduced with permission from Scheer et al. (2009).
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feeding condition [131–134]. In keeping with an important role
of peripheral circadian clocks in the temporal organization of
metabolism, transcriptome proﬁling in liver and heart has revealed
that many clock-controlled genes specify enzymes and regulators
involved in the metabolism of food components [87,88,135]. The
restricted daytime feeding protocol presents a condition very
much similar to that of many night shift workers, i.e., a misalign-
ment of the sleep/wake and fasting/feeding cycles on the one hand
and the L/D cycle on the other. Because of the entrainment of the
central pacemaker to the L/D cycle and the entrainment of periph-
eral clocks to the feeding/fasting cycle this situation could result in
internal desynchrony [136], which would lead to disturbed sleep,
reduced cognitive performance, and gastro-intestinal complaints,
i.e., symptoms very much similar to those of jet-lag. Not surpris-
ingly, a number of epidemiological studies have indicated a link
between shift work and increased risk for cardiovascular disease
and/or the metabolic syndrome [137–139].
Shift work is an extreme form of circadian misalignment. In a
milder form, circadian misalignment now features in the lives of
many as a result of a changing lifestyle. Using a simple question-
naire Roenneberg et al. investigated the sleep/wake habits of
>25 000 people and determined their chronotype [140,141]. They
concluded that not only shift workers but more than half of the
population lives with a body clock that is permanently out of phase
with environmental time, a condition they coined ‘‘social jetlag’’
[142]. Interestingly, many of these lifestyle changes also correlate
with an increased prevalence of the metabolic syndrome [143].
In their reviews Hastings et al. [144] and Foster and Wulff [145]
outlined how the misalignment of biological and social time may
cause circadian de-synchrony, possibly resulting in chronic ill-
nesses such as the metabolic syndrome, as well as cardio-vascular
and gastro-intestinal diseases.
7.1. Balancing the autonomic output of the SCN
Indeed, with the invention of the electric light bulb, the advent
of jet travel and the expansion of shift work, the daily cycles of rest
andwakefulness and their corresponding periods of fasting and eat-
ing, are no longer organized according to the presence of natural
light. Therefore, the normal alternation of sleep and wake, or rest
and activity, cold/warm, inactive/active and satiety/hunger cycles
is likely to be disturbed and the amplitude and coherence of these
SCN entraining signals is greatly reduced. We have put forward
the hypothesis that as a result of these diminished rhythmic inputs
to the SCN, the output of the SCN is diminished as well [146]. The
normal alternation of rest and activity is accompanied by a shift
in the balance of the ANS, i.e., the active period is characterized
by a predominant sympathetic activity, whereas parasympathetic
activity rules the body during the inactive period. This balance of
the ANS is critically dependent on the output of our biological clock.
Fig. 4 clearly illustrates how a shift of the L/D-cyclemay disorganize
SCN output. Subsequently, reduced amplitude, inappropriate tim-
ing, or internal desynchrony of the SCN output signals may result
in an unbalanced ANS and an organism less well prepared for the
upcoming demands. This idea is nicely illustrated by the results
of Cailotto et al. showing that nocturnal light exposure and a dis-
balance, but not a complete absence, of the autonomic inputs to
the liver result in a disturbed daily plasma glucose rhythm
[90,147,148]. Also the recent results of Fonken et al. [149], showing
that night time light exposure in mice results in increased body
mass and reduced glucose tolerance ﬁt in with this idea. We were
able to provide further strong supportive evidence for this hypoth-
esis in humans using a FD protocol. Subjects were subjected to
an 11-day protocol consisting of repeated 28-h ‘‘days’’, with 4
standardized meals per 28-h day. The misalignment between thefree-running central circadian pacemaker and the behavioral
sleep/wake and fasting/feeding rhythms, resulted in increased plas-
ma glucose and insulin concentrations, increased blood pressure
and decreased plasma leptin concentrations (Fig. 8) [75]. However,
these changes were in the absence of changes in vagal cardiac
modulation as estimated from heart rate variability and in the
absence of changes in sympathetic activity as estimated by urinary
epinephrine and norepinephrine. In 3 out of the 10 subjects the cir-
cadian disorganization pushed the postprandial glucose response
into the pre-diabetic range. This circadian misalignment also led
to a complete reversal of the rhythm of plasma cortisol and
melatonin across the sleep/wake cycle, which may be involved in
impaired glucose metabolism [150–152]. Circadian misalignment
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Scheer et al. [75] appeared to be beyond those that could be ex-
plained by changes in sleep efﬁciency per se, sleep quality in itself
also has clear effects on energy metabolism. As previously noted
there is a signiﬁcant correlation between sleep duration and the
risk of developing hypertension [100], diabetes [153] or obesity
[102,154]. Spiegel et al. [155] showed in healthy young volunteers
that restricting sleep to 4-h a night for 6 nights in a row resulted in
reduced glucose clearance, an impaired insulin response and insu-
lin resistance. Partial sleep deprivation has also been demonstrated
to result in lower plasma leptin and increased plasma ghrelin con-
centrations and in increased appetite and food intake [156–158], as
well as in a change in the autonomic balance [157].
8. A disorganized clock
Is there any direct evidence that a disorganized clock goes hand
in hand with metabolic disease? Not really, but there appears to be
some circumstantial evidence. The age-related deterioration that
has been observed in many daily endocrine, physiological and
behavioral rhythms in several species, including human, makes it
tempting to hypothesize a causative role for the declining output
of the SCN. Interestingly, a marked decrease in the number of
vasopressin-containing neurons occurs in subjects between 80
and 100 years of age and in subjects with Alzheimer’s disease
[20]. Also on the mRNA level vasopressin expression is lower in
the SCN of Alzheimer patients [159]. The ﬂattening of the daily
rhythm in vasopressin abundance was already observed in subjects
>50 years of age [160]. Similar decreases in the expression of
vasopressin in the SCN were also noted in aging experimental ani-
mals [161–163]. Harper et al. [164] very elegantly demonstrated
that the loss of SCN vasopressin-expressing neurons in the human
postmortem brain signiﬁcantly correlated with an increased dete-
rioration of activity rhythms before death. Further functional evi-
dence for disturbances of the SCN in patients from Alzheimer’s
disease comes from fractal analysis of actigraphy data, showing
breakdown of complexity of scale invariant behavior [165], very
similar to that demonstrated in locomotor activity of experimental
animals following lesioning of the SCN [166]. A similar situation is
apparent in patients with major depression, i.e., disturbed circa-
dian rhythms and a decreased activity of the vasopressinergic
SCN neurons [167]. Patients with diabetes or coronary heart dis-
ease have a ﬂattened melatonin rhythm [168–170]. Recently,
mutations in the melatonin receptor were linked to an increased
risk of type 2 diabetes [150–152], and some large scale genetic
studies in humans provided the ﬁrst evidence for the involvement
of disrupted clock gene rhythms in the pathogenesis of obesity and
type 2 diabetes. Speciﬁcally, haplotypes of the core clock genes
brain and muscle aryl hydrocarbon receptor nuclear translocator
(ARNT) like (Bmal1), circadian locomotor output cycles kaput
(CLOCK) and cryptochrome (CRY) were associated with either
obesity or type 2 diabetes [171–175]. Finally, a pronounced decline
of the immunocytochemical staining for three prominent SCN neu-
ropeptides – including vasopressin – was observed in subjects with
a history of primary hypertension [176]. This observation is all the
more interesting as a clear-cut increase was found in the amount of
CRH staining and CRH mRNA expression in the PVN in these same
patients [177]. The increased activity of CRH-neurons in the PVN of
hypertensive patients is probably not only responsible for an in-
creased activity of the HPA-axis, but also for an increased activity
of the sympathetic branch of the ANS, which has been implicated
in the pathogenesis of some forms of hypertension. The inverse
relationship between vasopressin and CRH as reﬂected by the de-
creased vasopressin staining in the SCN, and the increased CRH
activity in the PVN resembles the inhibitory effect of SCN-derived
vasopressin on the HPA-axis as found in the animal experiments.In other words, it is tempting to speculate that one of the mecha-
nisms underlying the increased CRH activity in hypertensive pa-
tients is a diminished inhibitory input from the SCN. In line,
spontaneously hypertensive rats (SHR) show a change in SCN
activity, although in this case it is an increased activity of the VIP
neurons [178,179]. The main question that remains is whether
these changes are a cause or a consequence of the disease.
9. Conclusion and perspectives
A key question at this stage is whether a strengthening of the
SCN signal could alleviate pathologies such as insulin resistance,
obesity and hypertension. Interestingly, the loss of immunoreactiv-
ity for SCN neurotransmitters during aging and hypertension is
probably not due to a loss of neurons, but to a decreased activity
of these neurons. Therefore, an important way to re-vitalize a ﬂat-
tened and disorganized SCN output might be to enhance the rhyth-
mic input signals to the SCN.
Indeed, increased light intensities during the light period ap-
peared to prevent the aging-induced decrease in SCN vasopressin
cell number in very old rats [180], as well as the deterioration of
their behavioral rhythms [181]. Moreover, in a recent double-blind,
placebo-controlled randomized study among 189 elderly residents
living in 12 different care facilities, long-term treatment with
whole-day bright light signiﬁcantly improved cognitive and non-
cognitive symptoms of dementia [182], extending earlier work
showing improved rest-activity cycles [183].
Anadditionalway to enhance the rhythmic input to theSCN is the
daily timed intake of melatonin. Melatonin is not only one of the
most stable hormonal outputs of the biological clock, it also has a
profound effect on the electrical activity of SCN neurons [184]. Re-
peated night time administration of exogenous melatonin might
therefore help to enhance the amplitude of the SCN rhythm by
dampening erroneous night time activity. We conducted a random-
ized, double-blind, placebo-controlled, crossover study in which 16
men with untreated essential hypertension were treated with oral
melatonin (2.5 mg daily; 1 h before sleep) for 3 weeks. Repeated
melatonin administration reduced blood pressure in hypertensive
patients by 4–6 mmHg, predominantly by a fall in systolic blood
pressure during sleep [185]. Thus, as with the daily light treatment
of elderly people, daily melatonin treatmentmay enhance the func-
tioning of the biological clock and thus help to improve circadian
rhythms in behavior. Another example may be gathered from stud-
ies showing thatdaily exercise is a very effectiveway to improveglu-
cose tolerance [186], with the most critical aspect probably being a
reduction of the periods of inactivity during thewaking hours [187].
The experiments described above provide possible therapeutic
strategies to counteract the negative health effects of a chronically
reduced SCN output. However, they may not apply for shift work-
ers, as here the circadian misalignment is in constant ﬂux. During
working days the shift worker is compelled to shift his/her sleep/
wake rhythm to meet the needs of work hours, but during days
off he/she reverts back to a normal daytime activity schedule to
meet the needs of social life. Therefore, future studies identifying
the exact mechanisms of internal desynchronization are justiﬁed
if we are to propose behavioral strategies capable of minimizing
the adverse effects of circadian misalignment.
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